1 BTC
=
- USD
Dynavax Technologies Corporation
As of May 30, 2026 at 24:05 UTC
Chart
About Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Market Statistics
Trading Metrics
How to Buy DVAX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy DVAX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesSanofi has completed its acquisition of Dynavax Technologies Corporation for $15.50 per share in cash. The deal includes Dynavax's hepatitis B vaccine HEPLISAV-B, a shingles vaccine candidate in phase 1/2 studies, and additional vaccine pipeline projects. The acquisition strengthens Sanofi's adult immunization portfolio by combining Dynavax's vaccines with Sanofi's global commercial reach and development capabilities. Dynavax shares ceased trading on NASDAQ on February 10, 2026.
Sanofi has completed its acquisition of Dynavax Technologies Corporation for $15.50 per share. The deal includes Dynavax's hepatitis B vaccine HEPLISAV-B, a shingles vaccine candidate (Z-1018) in Phase 1/2 trials, and other vaccine development projects. The acquisition strengthens Sanofi's position in adult vaccination with access to Dynavax's commercial reach and development capabilities. Dynavax shares will cease trading on NASDAQ effective February 10, 2026.
David Novack, President & COO of Dynavax Technologies, exercised and sold 114,000 shares for approximately $1.8 million on January 15, 2026, netting about $680,000 after costs. The sale comes following Dynavax's announcement of a $2.2 billion acquisition by French pharmaceutical giant Sanofi at $15.50 per share, representing a 40% premium to December closing prices.
Class action law firm Monteverde & Associates PC is investigating four merger and acquisition transactions: Dynavax Technologies' sale to Sanofi ($15.50/share), FONAR Corporation's sale to affiliates of its CEO ($19.00-$6.34/share), DigitalBridge Group's sale to SoftBank ($16.00/share), and ON24's sale to Cvent Atlanta ($8.10/share). The firm is seeking shareholders to determine if the proposed deal terms are fair.
Monteverde & Associates PC, a securities class action firm, has announced an investigation into Dynavax Technologies Corporation's proposed acquisition by Sanofi. Under the deal terms, Dynavax shareholders are expected to receive $15.50 per share in cash. The firm is examining whether the transaction represents a fair deal for shareholders.